|Dr. August James Troendle||Chairman, Pres & CEO||528.29k||N/A||1956|
|Mr. Jesse J. Geiger||CFO & COO of Laboratory Operations||529.52k||N/A||1974|
|Ms. Susan E. Burwig||Exec. VP of Operations||582.73k||N/A||1963|
|Mr. Stephen P. Ewald||Chief Compliance Officer, Gen. Counsel & Corp. Sec.||N/A||N/A||1969|
|Mr. Todd Meyers||VP of Bus. Devel. & Marketing||N/A||N/A||N/A|
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Medpace Holdings, Inc.’s ISS Governance QualityScore as of December 4, 2019 is 9. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 8; Compensation: 5.